This activity is intended for physicians, physician assistants/physician associates, nurse practitioners, registered nurses, pharmacists, social workers, and psychologists engaged in the care of patients with psychiatric illness.
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess diagnostic considerations and new and emerging therapies for the treatment of psychiatric illness.
Upon completion of this activity, participants should be able to:
Distinguish ADHD treatment-related adverse events from comorbid conditions
Identify the impact/burden of treatment-related adverse events on quality of life of patients with ADHD
Incorporate evidence-based strategies for management of treatment-related adverse events into care plans for patients experiencing adverse events from their ADHD treatment
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Greg W. Mattingly, MD
Associate Clinical Professor
Midwest Research Group
American Professional Society for ADHD and Related Disorders
St. Louis, Missouri
Greg W. Mattingly, MD: consultant/advisor/speaker: AbbVie, Acadia, Alkermes, Axsome, Corium, Eisai, Ironshore, Intracellular, Janssen, Lumos Labs, Lundbeck, MedPoint, Neos, Neurocrine, Noven, Otsuka, Redax, Roche, Rhodes, Sage, Skye Therapeutics, Sunovion, Supernus, Takeda, Teva, Trispharma; researcher: AbbVie, Acadia, Alkermes, Akilli, Axsome, Boehringer Ingelheim, Corium, Emalex, Idorsida, Janssen, Karuna, Lumos Labs, Medgenics, NLS-1 Pharma AG, Otsuka, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, Teva.
Jonathan M. Meyer, MD
Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Distinguished Life Fellow
American Psychiatric Association
San Diego, California
Jonathan Meyer, MD: consultant/advisor/speaker: Alkermes, Axsome, Cervel, Intra-Cellular Therapies, Karuna, Neurocrine, Noven, Otsuka America, Relmada, Sunovion Pharmaceuticals, Teva Pharmaceuticals.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Gabrielle Giacona and Michael Asbach, DMSc, PA-C, Psych-CAQ, as noted below.
Gabrielle Giacona: stock/stock options: AstraZeneca, Moderna.
Michael Asbach, DMSc, PA-C, Psych-CAQ: consultant/advisor/speaker: AbbVie, Avanir, Biogen, Janssen, Karuna, Neurocrine, Otsuka.
Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 13, 2023, through June 12, 2024:
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacology credit.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-162-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Assistant/Physician Associate Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until June 12, 2024. PAs should only claim commensurate with the extent of their participation.
Social Work Continuing Education
As a Jointly Accredited Organization, Clinical Care Options, LLC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1 clinical continuing education credit.
Psychologist Continuing Education
Continuing education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.
This activity offers 1 continuing education credit for psychologists.